Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis

Slide: 26 of 46

Meta-analysis of Discontinuation Trials of Biologic DMARDs

Randomized discontinuation trials include only patients who respond to a treatment during a run-in phase. These studies evaluate the sustainability of treatment effects.

Data from four discontinuation trials were combined in a meta-analysis to determine the risk of a disease flare for patients receiving biologic DMARDs when compared to those who discontinued treatment. The trials included only patients who failed to improve with methotrexate therapy. Study durations were 4 months to 2 years.

Result: The risk of a flare in patients who continued treatment was half that of those who discontinued treatment (relative risk = 0.48, 95% confidence interval = 0.36, 0.63).